Physician profile
Ganesh Chari
NPI 1215048061
$713.18
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $55.93 · 2021: $136 · 2022: $210 · 2023: $177 · 2024: $23.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $75.38 | 2020-2023 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $66.14 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $62.32 | 2022-2023 | Ultomiris |
| Lilly USA, LLC | $62.04 | 2019-2023 | Amyvid |
| Sk Life Science, INC. | $55.39 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $42.44 | 2019-2022 | |
| Acorda Therapeutics, INC | $38.78 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.44 | 2021 | |
| Genentech USA, INC. | $31.89 | 2022 | |
| Kyowa Kirin, INC. | $28.81 | 2021-2023 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $26.12 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $25.36 | 2021 | |
| Novo Nordisk INC | $23.35 | 2024 | |
| Abbvie INC. | $23.24 | 2023 | Qulipta |
| Biogen, INC. | $21.14 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $20.34 | 2022 | |
| Csl Behring | $18.24 | 2023 | Hizentra |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.09 | 2022 | |
| Ucb, INC. | $16.65 | 2019 | |
| Emd Serono, INC. | $13.17 | 2019 | |
| Avion Pharmaceuticals | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Chari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.